One hundred twenty-three patients with acquired severe and very severe aplastic anemia (VSAA) who were initially diagnosed from 2002 to 2012 and who received rATG (thymoglobulin) com- bined with intravenous or oral CsA, were enrolled in this study.SAA and VSAA were defined according to the standard criteria [13]